<qa>  What is the overall survival advantage in patients with intermediate-risk prostate cancer treated with RT?- Demonstrate an overall survival OS advantage in patients with intermediate-risk prostate cancer treated with dose-escalated radiotherapy RT with versus without short-term androgen-deprivation therapy ADT. 